NCT04436510View on ClinicalTrials.gov

HEALEY ALS Platform Trial - Regimen B Verdiperstat

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

167

Participants

Timeline

Start Date

July 28, 2020

Primary Completion Date

April 13, 2022

Study Completion Date

December 6, 2022

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

Matching Placebo

"Drug: Matching Placebo~Administration: Oral~Dose: two tablets twice daily"

DRUG

Verdiperstat

"Drug: Verdiperstat~Administration: Oral~Dose: 600mg twice daily"

Trial Locations (1)

02114

Healey Center for ALS at Mass General, Boston

Sponsors
All Listed Sponsors
collaborator

Biohaven Pharmaceuticals, Inc.

INDUSTRY

lead

Merit E. Cudkowicz, MD

OTHER